A cost-effectiveness analysis of bevacizumab (BV) plus chemotherapy (CT) versus aflibercept (AFLI) plus CT in patients with metastatic colorectal cancer (mCRC) previously treated with BV.
Robert Morlock
Employment or Leadership Position - Genentech
Elaine Yu
Employment or Leadership Position - Genentech
Joshua Ray
Employment or Leadership Position - Genentech